Title: ANTI-INFLAMMATORY MEDICAMENTS

Abstract: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C 07D 231/14; C 07D 249/12; C 07D 285/10; C 07D 403/12
US CL. : 548/135, 262.8, 364.1

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S.: 548/135, 262.8, 364.1; 546/183

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE - STN Structure search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US 3,939,122 (MERTEN et al.) 17 February 1976 (17.02.1976) at col. 12, lines 26 - 34 (chemical structure of 1,1'-(1,3-phenylene)bis[3-phenyl-2,4-imidazololidinedione]).</td>
<td>4</td>
</tr>
<tr>
<td>A</td>
<td>US 4,816,454 (ZOLLER et al.) 28 March 1989 (28.03.1989) at col. 15, lines 20-34 (&quot;Example 27&quot;).</td>
<td>4</td>
</tr>
<tr>
<td>A</td>
<td>US 5,621,010 (SUEDA, et al.) 15 April 1997 (15.04.1997), col. 54, line 40 et seq. (Example 81); col. 57, lines 1 - 51 (Example 86 and Example 87); col. 58, lines 1 - 51 (Example 88 and Example 89).</td>
<td>4</td>
</tr>
<tr>
<td>A, P</td>
<td>US 2003/0060455 A1 (MOSS and REGAN) 27 March 2003 (27.03.2003), page 30, col. 2, lines 20 - 22 (1-[5-tert-buty1-2-(2,5-dioxo-pyrolidin-1-y1)-phenyl]-3-[4-[6-(1H-imidazol-2-ylmethyl)-pyridin-3-y1]-naphthalen-1-y1]-urea); and page 27, col. 2, lines 37 - 39 (1-(2-methyl-1,3-dioxo-2,3 dihydro-1H-isooindol-5-y1)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-y1)naphthalen-1-y1]urea).</td>
<td>4</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

Date of the actual completion of the international search

02 May 2005 (05.05.2005)

Date of mailing of the international search report

02 JUN 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-8300

Authorized officer

Anthony J. Paviglianiti

Telephone No. (571) 272-3150

Form PCT/ISA/210 (second sheet) (July 1998)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US 6,080,763 (REGAN et al.) 27 June 2000 (27.06.2000) at col. 35, line 31 (&quot;compound 30&quot;); and col. 17, line 15 (pyrazole group) combined with col. 18, line 5 (phenyl group with hydroxy substituent group).</td>
<td>4</td>
</tr>
<tr>
<td>A</td>
<td>WO 00/55139 A2 (BETAGERI et al.) 21 September 2000 (21.09.2000), at page 79, lines 40-41 (1-[5-tert-butyl-2-(2,5-dioxo-pyrrrolidin-1-yl)-phenyl]-3-[4-[6-[(1H-imidazol-2-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl]urea); and at page 201, lines 4-9 (claim 1).</td>
<td>4</td>
</tr>
<tr>
<td>A, P</td>
<td>WO 03/084539 A2 (JUNG et al.) 16 October 2003 (16.10.2003), at page 88, lines 17-18 (1-(2-methyl-1,3-dioxo-2,3-dihydro-1H-isouindol-5-yl)-3-[4-(6-morpholin-4-ylmethylpyridin-3-yl)-naphthalen-1-yl]urea).</td>
<td>4</td>
</tr>
</tbody>
</table>
# INTERNATIONAL SEARCH REPORT

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. □ Claim Nos.;
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ✗ Claim Nos.: 1 - 3, 5 - 31
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
   Please See Continuation Sheet

3. □ Claim Nos.;
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. □ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

□ The additional search fees were accompanied by the applicant’s protest.

□ No protest accompanied the payment of additional search fees.
Continuation of Box I Reason 2:
The numerous variables, e.g., R1, X, Y, A, L, D, E, Y, Q, j, m, n, p, q, t, R4, Z, R5, R6, R8, R9, W, R7, G1, V, and W1, and their voluminous, complex meanings and their virtually incomprehensible permutations and combinations make it impossible to determine the full scope and complete meaning of the claimed subject matter. As presented, the claimed subject matter cannot be regarded as being a clear and concise description for which protection is sought and as such the listed claims do not comply with the requirements of PCT Article 6. Thus it is impossible to carry out a meaningful search on claims 1 - 3 and 5 - 31. A search will be carried out on the first discernable invention, which is claim 4.